Description

Tipranavir is a potent, non-peptidic protease inhibitor specifically designed for the treatment of Human Immunodeficiency Virus (HIV) infection. Its core value lies in its activity against HIV strains that have developed resistance to other protease inhibitors, making it a critical component of salvage therapy regimens. This active pharmaceutical ingredient (API) is essential for pharmaceutical manufacturers and research institutions developing advanced antiretroviral medications. Tipranavir CAS NO 174590-27-3 represents a key therapeutic agent in the global fight against multi-drug resistant HIV.

Application

• Pharmaceutical API: Primary use as the active ingredient in the formulation of antiretroviral drugs, specifically protease inhibitor medications.
• Combination HIV Therapy: Used in combination with ritonavir (as a pharmacokinetic enhancer) and other antiretrovirals for the treatment of HIV-1 infection in treatment-experienced adults.
• Drug-Resistant HIV Treatment: A vital therapeutic option for patients infected with HIV-1 strains that are resistant to multiple other protease inhibitors.
• Pharmaceutical Research & Development: Serves as a reference standard and key intermediate in R&D for novel HIV treatments and resistance studies.
• Clinical Trial Material: Supplied as a high-purity compound for use in clinical trials investigating new HIV treatment protocols or combination therapies.
• Analytical Testing: Used as a certified reference material in quality control laboratories for method development and validation of assay procedures.

Basic Information

Product Name	Tipranavir
CAS No.	174590-27-3
Molecular Formula	C31H33F3N2O5S
Molecular Weight	602.67 g/mol
Synonyms	PNU-140690; TPV; Tipranavirum; 4-Hydroxy-5,6-dihydro-4-[[1-[2-(1-methylethyl)-4-thiazolyl]-3-(trifluoromethyl)benzyl]amino]-2H-pyran-2-one; Aptivus (Brand Name); (4R,5S,6S)-4-Hydroxy-5,6-dihydro-4-({[2-(1-methylethyl)-1,3-thiazol-4-yl][3-(trifluoromethyl)phenyl]methyl}amino)-2H-pyran-2-one
EINECS	Contact for details

Quality Control

Our Tipranavir is manufactured under strict quality systems to ensure it meets the stringent requirements for pharmaceutical active ingredients. Each batch is subjected to comprehensive analytical testing, including identification, assay, impurity profiling, and residual solvent analysis, typically via HPLC, GC, and IR spectroscopy. We provide full traceability and support regulatory filings with detailed documentation. A Certificate of Analysis (COA) is supplied with every shipment, confirming compliance with agreed specifications and relevant ICH guidelines.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive) and must be kept under conditions that minimize exposure to atmospheric humidity to prevent degradation. For long-term storage, consider using desiccants.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Assay (HPLC)	98.0% - 102.0% (on anhydrous basis)
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%
Related Substances (HPLC)	Individual unknown impurity: ≤ 0.10% Total impurities: ≤ 1.0%
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.